Search

Gipson, Ilene, Ulla Mandel, Balaraj Menon, Sandra Michaud, Ann Tisdale, Diana Campos, and Henrik Clausen. 2017. “Generation and Characterization of a Monoclonal Antibody to the Cytoplasmic Tail of MUC16”. Glycobiology 27 (10): 920-26.

Syed, Zeba, Jennifer Tran, and Ula Jurkunas. 2017. “Peripheral Endothelial Cell Count Is a Predictor of Disease Severity in Advanced Fuchs Endothelial Corneal Dystrophy”. Cornea 36 (10): 1166-71.

AE, Takesian, Kotak VC, and Sanes DH. 2009. “Developmental Hearing Loss Disrupts Synaptic Inhibition: Implications for Auditory Processing”. Future Neurol 4 (3): 331-49.

Bakthavatchalam, Malini, Frank Lai, Shi Song Rong, Danny Ng, and Mårten Brelén. 2017. “Treatment of Cystoid Macular Edema Secondary to Retinitis Pigmentosa: A Systematic Review”. Surv Ophthalmol.

Foulsham, William, and Andrew Tatham. 2017. “High Altitude-Associated Changes in Intraocular Pressure Abrogated by Trabeculectomy”. J Glaucoma 26 (10): 957-60.

Inomata, Takenori, Alireza Mashaghi, Jiaxu Hong, Takeshi Nakao, and Reza Dana. 2017. “Scaling and Maintenance of Corneal Thickness During Aging”. PLoS One 12 (10): e0185694.

Wang, Jay, Inês Laíns, Joana Providência, Grayson Armstrong, Ana Santos, Pedro Gil, João Gil, et al. 2017. “Diabetic Choroidopathy: Choroidal Vascular Density and Volume in Diabetic Retinopathy With Swept-Source Optical Coherence Tomography”. Am J Ophthalmol 184: 75-83.

Marsh, Ashley Pl, Timothy Edwards, Charles Galea, Helen Cooper, Elizabeth Engle, Saumya Jamuar, Aurélie Méneret, et al. 2018. “DCC Mutation Update: Congenital Mirror Movements, Isolated Agenesis of the Corpus Callosum, and Developmental Split Brain Syndrome”. Hum Mutat 39 (1): 23-39.

Kim, Judy, Shipra Kanjlia, Lotfi Merabet, and Marina Bedny. 2017. “Development of the Visual Word Form Area Requires Visual Experience: Evidence from Blind Braille Readers”. J Neurosci 37 (47): 11495-504.

Durrani, Khayyam, John Kempen, Stephen Foster, and Systemic Immunosuppressive Therapy Eye Diseases (SITE) Research Group. 2017. “Authors Reply to Letter to the Editor- In Response To: Comment on Durrani et Al."s ‘Adalimumab for Ocular Inflammation’”. Ocul Immunol Inflamm, 1.